Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
CLRB Cellectar Biosciences	$5.23 +4.7%	$7.92	$4.36 ▼ $94.50	$9.45M	0.51	146,633 shs	96,864 shs
MBRX Moleculin Biotech	$0.84 +4.9%	$0.67	$0.25 ▼ $4.39	$25.41M	1.38	2.60 million shs	2.17 million shs
PXXLF POXEL FRANCE	$0.25	$0.25	$0.25 ▼ $0.25	N/A	-0.4	N/A	N/A
RGLS Regulus Therapeutics	$8.16	$8.07	$0.83 ▼ $8.35	$564.92M	0.35	1.01 million shs	N/A

These 7 Stocks Will Be Magnificent in 2025

Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2025. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
CLRB Cellectar Biosciences	0.00%	+2.25%	-43.00%	-42.68%	-93.40%
MBRX Moleculin Biotech	0.00%	+45.79%	+200.37%	-15.60%	-81.41%
PXXLF POXEL FRANCE	0.00%	0.00%	0.00%	0.00%	-64.29%
RGLS Regulus Therapeutics	0.00%	0.00%	+3.55%	+305.97%	+394.55%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
CLRB Cellectar Biosciences	2.2211 of 5 stars	3.2	2.0	0.0	0.0	1.4	1.7	1.3
MBRX Moleculin Biotech	2.2822 of 5 stars	3.5	2.0	0.0	0.0	0.6	1.7	1.3
PXXLF POXEL FRANCE	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
RGLS Regulus Therapeutics	1.6976 of 5 stars	2.1	5.0	0.0	0.0	0.6	3.3	0.0

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
CLRB Cellectar Biosciences	2.33	Hold	$375.00	6,947.55% Upside
MBRX Moleculin Biotech	3.00	Buy	$4.00	391.40% Upside
PXXLF POXEL FRANCE	0.00	N/A	N/A	N/A
RGLS Regulus Therapeutics	2.29	Hold	$8.50	4.17% Upside

Current Analyst Ratings Breakdown

Latest PXXLF, RGLS, MBRX, and CLRB Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
6/18/2025	MBRX Moleculin Biotech	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$4.00
6/9/2025	MBRX Moleculin Biotech	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Buy	$4.00
5/14/2025	CLRB Cellectar Biosciences	Maxim Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Hold
5/1/2025	RGLS Regulus Therapeutics	Wells Fargo & Company Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Overweight ➝ Equal Weight	$9.00
4/30/2025	RGLS Regulus Therapeutics	Wells Fargo & Company Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Strong-Buy ➝ Hold
4/30/2025	RGLS Regulus Therapeutics	Leerink Partnrs Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Strong-Buy ➝ Hold
4/30/2025	RGLS Regulus Therapeutics	Leerink Partners Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform ➝ Market Perform	$7.00
4/30/2025	RGLS Regulus Therapeutics	Canaccord Genuity Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Hold	$28.00 ➝ $11.00
4/30/2025	RGLS Regulus Therapeutics	Jones Trading Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Hold	$8.00 ➝ $7.00

(Data available from 7/21/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
CLRB Cellectar Biosciences	N/A	N/A	N/A	N/A	$8.98 per share	N/A
MBRX Moleculin Biotech	N/A	N/A	N/A	N/A	$1.77 per share	N/A
PXXLF POXEL FRANCE	$710K	N/A	N/A	N/A	N/A	N/A
RGLS Regulus Therapeutics	N/A	N/A	N/A	N/A	$1.17 per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
CLRB Cellectar Biosciences	-$44.58M	-$21.92	N/A	N/A	N/A	N/A	-619.70%	-158.04%	8/13/2025 (Estimated)
MBRX Moleculin Biotech	-$21.76M	N/A	0.00	N/A	N/A	N/A	-278.80%	-100.11%	8/4/2025 (Estimated)
PXXLF POXEL FRANCE	-$33.08M	N/A	0.00	∞	N/A	N/A	N/A	N/A	N/A
RGLS Regulus Therapeutics	-$46.36M	-$0.73	N/A	N/A	N/A	N/A	-57.53%	-53.26%	8/6/2025 (Estimated)

Latest PXXLF, RGLS, MBRX, and CLRB Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/14/2025	Q2 2025	RGLS Regulus Therapeutics	-$0.23	N/A	N/A	N/A	N/A	N/A
8/13/2025	Q2 2025	CLRB Cellectar Biosciences	-$3.70	N/A	N/A	N/A	N/A	N/A
8/12/2025	Q2 2025	MBRX Moleculin Biotech	-$0.42	N/A	N/A	N/A	N/A	N/A
5/13/2025	Q1 2025	CLRB Cellectar Biosciences	-$5.10	-$3.90	+$1.20	-$0.14	N/A	N/A
5/13/2025	Q1 2025	MBRX Moleculin Biotech	-$0.71	-$0.69	+$0.02	-$0.69	N/A	N/A
5/8/2025	Q1 2025	RGLS Regulus Therapeutics	-$0.29	-$0.15	+$0.14	-$0.15	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
CLRB Cellectar Biosciences	N/A	N/A	N/A	N/A	N/A
MBRX Moleculin Biotech	N/A	N/A	N/A	N/A	N/A
PXXLF POXEL FRANCE	N/A	N/A	N/A	N/A	N/A
RGLS Regulus Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
CLRB Cellectar Biosciences	N/A	2.47	2.47
MBRX Moleculin Biotech	N/A	1.35	1.35
PXXLF POXEL FRANCE	N/A	N/A	N/A
RGLS Regulus Therapeutics	N/A	16.31	16.31

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
CLRB Cellectar Biosciences	16.41%
MBRX Moleculin Biotech	15.52%
PXXLF POXEL FRANCE	N/A
RGLS Regulus Therapeutics	92.38%

Insider Ownership

Company	Insider Ownership
CLRB Cellectar Biosciences	5.04%
MBRX Moleculin Biotech	2.10%
PXXLF POXEL FRANCE	N/A
RGLS Regulus Therapeutics	4.35%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
CLRB Cellectar Biosciences	10	1.81 million	1.72 million	Optionable
MBRX Moleculin Biotech	20	30.21 million	29.57 million	Not Optionable
PXXLF POXEL FRANCE	15	N/A	N/A	Not Optionable
RGLS Regulus Therapeutics	30	69.23 million	66.22 million	Optionable

PXXLF, RGLS, MBRX, and CLRB Headlines

Recent News About These Companies

Regulus Therapeutics Inc. (NASDAQ:RGLS) Receives $8.50 Average PT from Brokerages

July 17, 2025 | americanbankingnews.com

Novartis (NVS) Acquires Regulus Therapeutics for $1.7 Billion

June 28, 2025 | finance.yahoo.com

Regulus Therapeutics (NASDAQ:RGLS) Upgraded at Wall Street Zen

June 27, 2025 | marketbeat.com

Novartis concludes acquisition of Regulus Therapeutics

June 26, 2025 | medicaldialogues.inM

Novartis concludes Regulus Therapeutics acquisition

June 26, 2025 | pharmaceutical-technology.comP

Press Release: Novartis completes acquisition of Regulus Therapeutics

June 25, 2025 | finanzen.atF

Novartis completes acquisition of Regulus Therapeutics

June 25, 2025 | globenewswire.com

Novartis announces expiration of HSR waiting period of Regulus Therapeutics tender offer

June 24, 2025 | pharmabiz.comP

Regulus Therapeutics Inc.

June 21, 2025 | barrons.com

Regulus Therapeutics Inc. (NASDAQ:RGLS) Insider Preston Klassen Acquires 12,000 Shares

June 5, 2025 | insidertrades.com

Insider Buying: Preston Klassen Acquires 12,000 Shares of Regulus Therapeutics Inc (RGLS)

June 4, 2025 | gurufocus.com

Regulus Therapeutics: An Undervalued Buy, With A $0.90 CVR And A $7 Payout

June 4, 2025 | seekingalpha.com

Novartis commences tender offer to acquire Regulus Therapeutics

May 29, 2025 | pharmabiz.comP

Novartis emerged victorious in multi-month pursuit of Regulus and potential kidney blockbuster, filing shows

May 29, 2025 | fiercepharma.comF

Novartis arm commences tender offer to buy Regulus Therapeutics

May 28, 2025 | medicaldialogues.inM

Latham and Covington Advise on Novartis’s Acquisition of Regulus

May 16, 2025 | lawstreetmedia.comL

Regulus Therapeutics Inc.: Regulus Therapeutics Reports First Quarter 2025 Financial Results and Recent Updates

May 9, 2025 | finanznachrichten.de

Regulus Therapeutics Reports First Quarter 2025 Financial Results and Recent Updates

May 8, 2025 | prnewswire.com

REGULUS THERAPEUTICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Regulus Therapeutics Inc. - RGLS

May 4, 2025 | businesswire.com

Novartis (NVS) To Acquire Regulus Therapeutics in $0.8 Billion Deal

May 4, 2025 | gurufocus.com

Wells Fargo Downgrades Regulus Therapeutics (RGLS)

May 2, 2025 | msn.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

PXXLF, RGLS, MBRX, and CLRB Company Descriptions

Cellectar Biosciences NASDAQ:CLRB

$5.22 +0.24 (+4.71%)

As of 02:43 PM Eastern

Cellectar Biosciences, Inc., a clinical biopharmaceutical company, focuses on the discovery, development, and commercialization of drugs for the treatment of cancer. Its lead phospholipid drug conjugate (PDC) candidate is CLR 131 (iopofosine I-131), which is in Phase 2 clinical study for patients with B-cell malignancies; Phase 2a clinical study for patients with relapsed or refractory (r/r) Waldenstrom's macroglobulinemia cohort, r/r multiple myeloma (MM) cohort, and r/r non-Hodgkin's lymphoma cohort; Phase 1 clinical study for r/r pediatric patients with select solid tumors, lymphomas, and malignant brain tumors; and Phase 1 clinical study for r/r head and neck cancer. The company also develops CLR 1900, a PDC chemotherapeutic program that is in the preclinical development stage to treat solid tumors. It has collaborative with Orano Med to develop CLR 12120 Series; and LegoChemBio. The company was founded in 2002 and is headquartered in Florham Park, New Jersey.

Moleculin Biotech NASDAQ:MBRX

$0.84 +0.04 (+4.86%)

As of 02:43 PM Eastern

Moleculin Biotech, Inc., a clinical stage pharmaceutical company, focuses on the development of drug candidates for the treatment of cancers and viruses. Its lead drug candidate is Annamycin, which is in Phase 1B/2 clinical trials for the treatment of relapsed or refractory acute myeloid leukemia (AML) and soft tissue sarcoma metastasized to the lungs. The company is also developing WP1066, an immune/transcription modulator designed to inhibit phosphorylated signal transducer and activator of transcription and other oncogenic transcription factors targeting brain tumors, and pancreatic and other cancers. In addition, it develops WP1220, an analog of WP1066 for the topical treatment of cutaneous T-cell lymphoma; and WP1122 to treat viruses, as well as cancer indications, including brain tumors, and pancreatic and other cancers. The company was incorporated in 2015 and is headquartered in Houston, Texas.

POXEL FRANCE OTCMKTS:PXXLF

$0.25 0.00 (0.00%)

As of 07/18/2025

Poxel S.A., a clinical-stage biopharmaceutical company, develops novel treatments for metabolic diseases, type 2 diabetes, and liver diseases. The company's lead product is TWYMEEG (Imeglimin), an oral drug candidate that targets mitochondrial dysfunction and approved for the treatment of type 2 diabetes in Japan. It also develops PXL770, an adenosine monophosphate-activated protein kinase enzyme, which is in a Phase 2a clinical trial that treats chronic metabolic diseases, including diseases that affect the liver, such as non-alcoholic steatohepatitis (NASH); PXL065, an earlier stage programs that is in Phase 2 for the treatment of NASH focusing on chronic and rare metabolic indications. The company has a licensing agreement with Enyo Pharma S.A.S. for the development of farnesoid X receptor that is in Phase 2a study for the treatment of hepatitis B and NASH; and DeuteRx LLC for the development of PXL065, a mitochondrial pyruvate carrier inhibitor, which is in a phase I clinical trial for the treatment of NASH. Poxel S.A. was incorporated in 2009 and is headquartered in Lyon, France.

Regulus Therapeutics NASDAQ:RGLS

$8.16 0.00 (0.00%)

As of 06/25/2025

Regulus Therapeutics Inc., a clinical-stage biopharmaceutical company, focuses on discovery and development of drugs that targets microRNAs to treat a range of diseases in the United States. Its product candidates include RGLS8429, an anti-miR next generation oligonucleotide targeting miR-17, which is in Phase 1b clinical trial for the treatment of autosomal dominant polycystic kidney disease. The company is also developing a pipeline of preclinical drug products for target organ-selective delivery strategies. Regulus Therapeutics Inc. was incorporated in 2007 and is headquartered in San Diego, California.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time